Intersect ENT (XENT)

P/S ratio at the end of 2021: 8.56

According to Intersect ENT's latest financial reports and stock price the company's current price-to-sales ratio (TTM) is N/A. At the end of 2021 the company had a P/S ratio of 8.56.

P/S ratio history for Intersect ENT from 2014 to 2021

PS ratio at the end of each year

Year	P/S ratio	Change
2021	8.56	-8.57%
2020	9.36	27.32%
2019	7.35	-7.93%
2018	7.99	-19.4%
2017	9.91	125.68%
2016	4.39	-57.31%
2015	10.3	-8.48%
2014	11.2

P/S ratio for similar companies or competitors

Company	P/S ratio	P/S ratio differencediff.	Country
Ocular Therapeutix OCUL	23.1	N/A	🇺🇸 USA
Anika Therapeutics ANIK	1.48	N/A	🇺🇸 USA
Haemonetics HAE	3.03	N/A	🇺🇸 USA
ICON plc ICLR	2.02	N/A	🇮🇪 Ireland

What is the market capitalization of a company?

The market capitalization sometimes referred as Marketcap, is the value of a publicly listed company.
In most cases it can be easily calculated by multiplying the share price with the amount of outstanding shares.

DISCLAIMER

CompaniesMarketCap is not associated in any way with CoinMarketCap.com
Stock prices are delayed, the delay can range from a few minutes to several hours.
Company logos are from the CompaniesLogo.com logo database and belong to their respective copyright holders. Companies Marketcap displays them for editorial purposes only.

Contact

For inquiries or if you want to report a problem write to hello@8marketcap.com

Links

- Privacy policy

- Terms and conditions

P/S ratio for Intersect ENT (XENT)

P/S ratio at the end of 2021: 8.56